查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1536675

糖尿病神经病变治疗市场，按疾病类型、药物类别、配销通路、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Diabetic Neuropathy Treatment Market, By Disease Type, By Drug Class, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 288 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2023年糖尿病神经病变治疗市场规模为43.9032亿美元，2024年至2032年复合年增长率为8.10%。

糖尿病神经病变治疗市场-市场动态

糖尿病治疗诊断技术的改进和创新疗法预计将推动市场需求

全球糖尿病（尤其是第 2 型糖尿病）发生率的不断上升是市场成长的关键驱动力。随着糖尿病患者数量的增加，对糖尿病神经病变等併发症的有效治疗的需求也在增加。诊断技术的进步和认识的提高可以更早、更准确地诊断糖尿病神经病变。早期诊断通常会带来更好的管理和治疗结果，从而增加对治疗的需求。新兴市场更高的医疗支出和改善的医疗基础设施有助于糖尿病神经病变治疗市场的成长。

增加对研究和新疗法的投资，包括新型药物、生物製剂和医疗设备，有助于市场成长。药物输送系统和治疗方法的创新增强了治疗选择。政府对糖尿病研究和治疗的倡议和资助，以及糖尿病神经病变治疗的优惠报销政策，支持了市场成长。新药物和疗法引入市场，包括针对特定神经性疼痛途径或提供更好疗效和安全性的药物和疗法，推动了市场成长。

糖尿病神经病变治疗市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 8.10% 左右的复合年增长率成长

根据疾病类型细分，预计週边神经病变细分市场将在 2023 年显示最大的市场份额，因为它是最常见的糖尿病神经病变形式之一。

根据药物类别细分，非类固醇抗发炎药物 (NSAID) 因其市场可承受性而成为 2023 年领先的药物类别。

根据配销通路细分，由于医院药房的用药量较高，医院药房细分市场将成为 2023 年的主要配销通路。

从地区来看，由于拥有发达的糖尿病治疗医疗基础设施，北美将成为 2023 年的主要收入来源。

糖尿病神经病变治疗市场-細項分析：

全球糖尿病神经病变治疗市场根据疾病类型、药物类别、配销通路和地区进行细分。

根据疾病类型，市场分为四类：週边神经病变、自主神经病变、近端神经病变和局部神经病变。週边神经病变领域主导市场。老年人中糖尿病的高盛行率正在推动细分市场的需求。

依药物类别，市场分为四类：辣椒素、鸦片类药物、非类固醇抗发炎药（NSAID）等。非类固醇抗发炎药（NSAID）预计将占据最大的市场份额。据估计，阿片类药物市场在预测期内将以最快的速度成长。鸦片类药物是强效镇痛药，可以更有效地缓解疼痛。

根据分销管道，市场分为三类：医院药房、零售药房和其他。医院药房领域在市场中占据主导地位，预计在预测期内将保持其较高的主导地位。医院药房拥有一个用于管理药物的整合系统，这使得处理更容易，因此得到了更多的采用。

糖尿病神经病变治疗市场 - 地理洞察

从地理来看，该市场广泛分布于北美、拉丁美洲、欧洲、亚太、中东和非洲等地区。由于糖尿病盛行率高和医疗基础设施先进，北美（主要是美国）在全球糖尿病神经病变治疗市场中占有重要份额。由于糖尿病发病率上升和医疗基础设施改善，包括中国和印度等国家在内的亚太地区糖尿病神经病变治疗市场正在快速成长。

糖尿病神经病变治疗市场-竞争格局：

糖尿病神经病变治疗市场竞争适中，有许多公司参与开发和提供糖尿病治疗解决方案。市场参与者正在开发与糖尿病神经病变相关的特定疼痛途径的新药，包括新配方和标靶治疗。由于糖尿病盛行率上升和医疗基础设施不断扩大，公司越来越关注亚太和拉丁美洲等新兴市场。

最新进展：

2023 年 12 月，Vertex Pharmaceuticals 获得 FDA 批准基于 CRISPR 的基因编辑疗法，这是一项专注于开发非鸦片类疼痛管理药物的策略性倡议。

2023 年 7 月，印度製药公司 Asprius Lifesciences 推出了一种针对糖尿病神经病变（一种导致神经损伤的疾病）的治疗方法。

2022 年，Axovant 基因疗法正在探索先进的治疗方法，包括神经系统疾病的基因和细胞疗法。

目录

第一章：糖尿病神经病变治疗市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按疾病类型分類的糖尿病神经病变治疗市场片段
    • 按药物类别分類的糖尿病神经病变治疗市场片段
    • 按配销通路分類的糖尿病神经病变治疗市场片段
    • 按国家/地区分類的糖尿病神经病变治疗市场片段
    • 按地区分類的糖尿病神经病变治疗市场片段
  • 竞争洞察

第 3 章：糖尿病神经病变治疗主要市场趋势

  • 糖尿病神经病变治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 糖尿病神经病变治疗市场限制
    • 市场限制影响分析
  • 糖尿病神经病变治疗市场机会
  • 糖尿病神经病变治疗市场未来趋势

第 4 章：糖尿病神经病变治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：糖尿病神经病变治疗市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：糖尿病神经病变治疗市场格局

  • 2023 年糖尿病神经病变治疗市占率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：糖尿病神经病变治疗市场 - 依疾病类型

  • 概述
    • 按疾病类型分類的细分市场份额分析
    • 週边神经病变
    • 自主神经病变
    • 近端神经病变
    • 局部神经病变

第 8 章：糖尿病神经病变治疗市场 - 依药物类别

  • 概述
    • 按药物类别分類的细分市场份额分析
    • 辣椒素
    • 阿片类药物
    • 非类固醇类抗发炎药 (NSAID)
    • 其他的

第 9 章：糖尿病神经病变治疗市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院药房
    • 零售药局
    • 其他的

第 10 章：糖尿病神经病变治疗市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美糖尿病神经病变治疗主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按疾病类型）
    • 北美市场规模和预测（按药物类别）
    • 北美市场规模和预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲糖尿病神经病变治疗主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模与预测（按疾病类型）
    • 欧洲市场规模和预测（按药物类别）
    • 欧洲市场规模和预测（按配销通路）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区糖尿病神经病变治疗主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（按疾病类型）
    • 亚太地区市场规模和预测（按药物类别）
    • 亚太地区市场规模和预测（按配销通路）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲糖尿病神经病变治疗主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按疾病类型）
    • 拉丁美洲市场规模与预测（按药物类别）
    • 拉丁美洲市场规模和预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲糖尿病神经病变治疗主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按疾病类型）
    • 中东和非洲市场规模及预测（按药物类别）
    • 中东和非洲市场规模及预测（按配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - 糖尿病神经病变治疗产业

  • 竞争仪表板
  • 公司简介
    • Pfizer Inc.
    • Eli Lilly and Company
    • Astellas Pharma Inc.
    • GlaxoSmithKline plc.
    • Boehringer Ingelheim
    • NeuroMetrix Inc.
    • Axovant Gene Therapies Ltd.
    • Eton Pharmaceuticals
    • Alnylam Pharmaceuticals
    • Novartis International AG
    • Sanofi
    • Johnson & Johnson
    • Amgen Inc.
    • AbbVie Inc.
    • Merck & Co.
    • Vertex Pharmaceuticals
    • Others

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
Product Code: ANV3524

REPORT HIGHLIGHT

Diabetic Neuropathy Treatment Market size was valued at USD 4,390.32 Million in 2023, expanding at a CAGR of 8.10% from 2024 to 2032.

Diabetic neuropathy is a type of nerve damage that can occur in people with diabetes, usually because of prolonged high blood sugar levels. Treatment typically focuses on managing symptoms and preventing further nerve damage.

Diabetic Neuropathy Treatment Market- Market Dynamics

Improved diagnostic techniques in diabetes treatment and innovative therapies are expected to propel market demand

The growing incidence of diabetes, particularly type 2 diabetes, worldwide is a key driver of the market growth. As the number of diabetes patients increases, so does the demand for effective treatments for complications such as diabetic neuropathy. Advances in diagnostic technologies and increased awareness lead to earlier and more accurate diagnosis of diabetic neuropathy. Early diagnosis often leads to better management and treatment outcomes, increasing the demand for therapies. Higher healthcare spending and improved healthcare infrastructure in emerging markets contribute to the growth of the diabetic neuropathy treatment market.

Increasing investment into research & new treatments and therapies, including novel pharmaceuticals, biologics, and medical devices, contributes to market growth. Innovations in drug delivery systems and therapeutic approaches enhance treatment options. Government initiatives and funding for diabetes research and treatment, as well as favorable reimbursement policies for diabetic neuropathy therapies, support market growth. The introduction of new drugs and therapies into the market, including those targeting specific neuropathic pain pathways or providing better efficacy and safety profiles, drives market growth.

Diabetic Neuropathy Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.10% over the forecast period (2024-2032)

Based on Disease Type segmentation, the peripheral neuropathy segment was predicted to show maximum market share in the year 2023, as it is one of the most common forms of diabetic neuropathy.

Based on Drug Class segmentation, the non-steroidal anti-inflammatory drugs (NSAIDs) segment was the leading Drug Class in 2023, due to its affordability in the market.

Based on Distribution Channel segmentation, the hospital pharmacies segment was the leading Distribution Channel in 2023, owing to high medication at hospital pharmacies.

On the basis of region, North America was the leading revenue generator in 2023, owing to the presence of developed healthcare infrastructure for diabetic treatment.

Diabetic Neuropathy Treatment Market- Segmentation Analysis:

The Global Diabetic Neuropathy Treatment Market is segmented on the basis of Disease Type, Drug Class, Distribution Channel, and Region.

The market is divided into four categories based on Disease Type: peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. The peripheral neuropathy segment dominates the market. The high prevalence of diabetes among old adults is boosting segment demand.

The market is divided into four categories based on Drug Class: capsaicin, opioid, Non-Steroidal Anti-inflammatory Drugs (NSAIDs), and others. The Non-Steroidal Anti-inflammatory Drugs (NSAIDs) segment is projected to hold the largest share of the market. The opioid segment is estimated to grow at the fastest rate over the forecast period. Opioids are potent analgesics that can provide more effective pain relief.

The market is divided into three categories based on Distribution channels: hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment dominates the market and is expected to maintain its high dominance during the forecast period. Hospital pharmacies have an integrated system for managing medications, which makes it easier to process and hence have greater adoption.

Diabetic Neuropathy Treatment Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America, predominantly the United States, holds a significant share of the global diabetic neuropathy treatment market due to a high prevalence of diabetes and advanced healthcare infrastructure. The Asia-Pacific region, including countries like China and India, is experiencing rapid growth in the diabetic neuropathy treatment market due to rising diabetes rates and improving healthcare infrastructure.

Diabetic Neuropathy Treatment Market- Competitive Landscape:

The diabetic neuropathy treatment market is moderately competitive, with numerous companies involved in developing and offering diabetic treatment solutions. Market players are working on novel drugs targeting specific pain pathways associated with diabetic neuropathy including new formulations and targeted therapies. Companies are increasingly focusing on emerging markets such as Asia-Pacific and Latin America due to the rising prevalence of diabetes and expanding healthcare infrastructure.

Recent Developments:

In December 2023, Vertex Pharmaceuticals got FDA approval for CRISPR-based gene editing therapy, a strategic move which focuses on the development of non-opioid pain management drugs.

In July 2023, Asprius Lifesciences, an Indian pharmaceutical company, has launched a treatment for Diabetic Neuropathy, a condition causing nerve damage.

In 2022, Axovant Gene Therapies is exploring advanced treatments including gene and cell therapies for neurological conditions.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET KEY PLAYERS

  • Pfizer Inc.
  • Eli Lilly and Company
  • Astellas Pharma Inc.
  • GlaxoSmithKline plc.
  • Boehringer Ingelheim
  • NeuroMetrix Inc.
  • Axovant Gene Therapies Ltd.
  • Eton Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Novartis International AG
  • Sanofi
  • Johnson & Johnson
  • Amgen Inc.
  • AbbVie Inc.
  • Merck & Co.
  • Vertex Pharmaceuticals
  • Others

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2019-2032

  • Peripheral neuropathy
  • Autonomic neuropathy
  • Proximal neuropathy
  • Focal neuropathy

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019-2032

  • Capsaicin
  • Opioid
  • Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
  • Others

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019-2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Diabetic Neuropathy Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Diabetic Neuropathy Treatment Market Snippet by Disease Type
    • 2.1.2. Diabetic Neuropathy Treatment Market Snippet by Drug Class
    • 2.1.3. Diabetic Neuropathy Treatment Market Snippet by Distribution Channel
    • 2.1.4. Diabetic Neuropathy Treatment Market Snippet by Country
    • 2.1.5. Diabetic Neuropathy Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Diabetic Neuropathy Treatment Key Market Trends

  • 3.1. Diabetic Neuropathy Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Diabetic Neuropathy Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Diabetic Neuropathy Treatment Market Opportunities
  • 3.4. Diabetic Neuropathy Treatment Market Future Trends

4. Diabetic Neuropathy Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Diabetic Neuropathy Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Diabetic Neuropathy Treatment Market Landscape

  • 6.1. Diabetic Neuropathy Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Diabetic Neuropathy Treatment Market - By Disease Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Disease Type, 2024 & 2032 (%)
    • 7.1.2. Peripheral neuropathy
    • 7.1.3. Autonomic neuropathy
    • 7.1.4. Proximal neuropathy
    • 7.1.5. Focal neuropathy

8. Diabetic Neuropathy Treatment Market - By Drug Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
    • 8.1.2. Capsaicin
    • 8.1.3. Opioid
    • 8.1.4. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
    • 8.1.5. Others

9. Diabetic Neuropathy Treatment Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Others

10. Diabetic Neuropathy Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Diabetic Neuropathy Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Diabetic Neuropathy Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Diabetic Neuropathy Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Diabetic Neuropathy Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Diabetic Neuropathy Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Diabetic Neuropathy Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
    • 11.2.2. Eli Lilly and Company
    • 11.2.3. Astellas Pharma Inc.
    • 11.2.4. GlaxoSmithKline plc.
    • 11.2.5. Boehringer Ingelheim
    • 11.2.6. NeuroMetrix Inc.
    • 11.2.7. Axovant Gene Therapies Ltd.
    • 11.2.8. Eton Pharmaceuticals
    • 11.2.9. Alnylam Pharmaceuticals
    • 11.2.10. Novartis International AG
    • 11.2.11. Sanofi
    • 11.2.12. Johnson & Johnson
    • 11.2.13. Amgen Inc.
    • 11.2.14. AbbVie Inc.
    • 11.2.15. Merck & Co.
    • 11.2.16. Vertex Pharmaceuticals
    • 11.2.17. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Diabetic Neuropathy Treatment Market: Disease Type Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Disease Type
  • TABLE Global Diabetic Neuropathy Treatment Market, by Disease Type 2019-2032 (USD Million)
  • TABLE Diabetic Neuropathy Treatment Market: Drug Class Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Diabetic Neuropathy Treatment Market, by Drug Class 2019-2032 (USD Million)
  • TABLE Diabetic Neuropathy Treatment Market: Distribution Channel Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Diabetic Neuropathy Treatment Market, by Distribution Channel 2019-2032 (USD Million)
  • TABLE Diabetic Neuropathy Treatment Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Diabetic Neuropathy Treatment Market, by Region 2019-2032 (USD Million)
  • TABLE North America Diabetic Neuropathy Treatment Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Diabetic Neuropathy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • TABLE North America Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE North America Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Europe Diabetic Neuropathy Treatment Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Diabetic Neuropathy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • TABLE Europe Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Europe Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Asia Pacific Diabetic Neuropathy Treatment Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Diabetic Neuropathy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • TABLE Asia Pacific Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Asia Pacific Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Latin America Diabetic Neuropathy Treatment Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Diabetic Neuropathy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • TABLE Latin America Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Latin America Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Diabetic Neuropathy Treatment Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Diabetic Neuropathy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)